MAIA Biotechnology, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MAIA Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $38.55K, a 4467.42% increase year-over-year.
- MAIA Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $844.00.
- MAIA Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $30.19K, a 2006.77% increase year-over-year.
- MAIA Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $185.65K.
- MAIA Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $844.00, a 99.61% decline from fiscal 2024.
- MAIA Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $217.16K, a 15054.08% increase from fiscal 2023.
- MAIA Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.43K, a 98.29% decline from fiscal 2022.
- MAIA Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $84.00K, a 833.33% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $38.55K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $844.00 10-K · filed 2026-03-23 | |
| 2025-03-31 | $844.00 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $217.16K 10-K · filed 2026-03-23 | |
| 2024-09-30 | $30.19K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $185.65K 10-Q · filed 2025-11-07 | |
| 2023-12-31 | $1.43K 10-K · filed 2025-03-21 | |
| 2023-09-30 | $1.43K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $84.00K 10-K · filed 2024-03-21 | |
| 2022-09-30 | $18.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $47.70K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $9.00K 10-K · filed 2023-03-24 | |
| 2021-03-31 | $5.40K 10-Q/A · filed 2023-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |